ClinicalTrials.Veeva

Menu

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Dyslipidemia

Treatments

Drug: CP-778,875

Study type

Interventional

Funder types

Industry

Identifiers

NCT00326326
A5561005

Details and patient eligibility

About

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Sex

All

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
  • Triglycerides between 150-500 mg/dL
  • Fasting Plasma Glucose 140-240 mg/dL

Exclusion criteria

  • Known cardiovascular, carotid, or peripheral vascular disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

31

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems